查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1766138

愛德華茲症候群治療市場預測（至 2032 年）：按治療類型、類型、最終用戶和地區進行的全球分析

Edward's Syndrome Treatment Market Forecasts to 2032 - Global Analysis By Treatment Type (Supportive Care/Palliative Care, Potential Future Therapies and Other Treatment Types), Type, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球愛德華茲症候群治療市場預計在 2025 年將達到 56 億美元，到 2032 年將達到 89 億美元，預測期內的複合年成長率為 6.9%。愛德華茲症候群（18 三體）沒有明確的治療方法，治療以支持治療和安寧療護為主。醫療介入旨在控制危及生命的併發症，例如心臟缺陷、飲食障礙和呼吸問題。新生兒可能需要新生兒加護治療，長期倖存者可受益於多學科支援以改善他們的生活品質。這通常取決於症狀的嚴重和家庭的意願。此方法強調舒適度、道德考量和個人化的護理計劃。

根據《兒科學雜誌》 2022 年的一篇評論，大約 50% 的愛德華茲氏症嬰兒能夠活過出生後的第一周，但即使經過精心醫療護理，也只有不到 10% 的嬰兒能夠活過 1 歲。

更重視安寧療護與舒適護理

愛德華茲氏症候群的治療格局已發生顯著變化，人們更加重視改善這種危及生命的疾病患者的生活品質。由於目前尚無確定性的治療方法，醫療重點已轉向透過症狀管理和安寧療護來提高患者的舒適度。醫療保健提供者優先考慮支持性護理策略，以最大限度地減輕患者的痛苦並改善其功能健康，尤其是在新生兒和嬰兒早期。

死亡率高，預期壽命短

大多數患者活不過出生後一年，影響了綜合治療性介入介入的發展空間。如此短的預期壽命往往導致醫療方法更為保守，而較少重視積極治療。此外，侵入性手術決策過程中的情緒和倫理挑戰進一步限制了治療的普及。

投資罕見疾病研究和孤兒藥認定

罕見疾病治療計畫等策略性資金鼓勵製藥公司研究標靶治療，以服務這些醫療資源匱乏的病患群體。政府和監管機構提供快速核准途徑和財政獎勵，以鼓勵產前檢測和基因調控療法的創新。學術機構也與生技公司合作，利用分子研究探索新的治療方法。

錯誤訊息和不一致訊息

關於治療方案（尤其是維持生命的干涉措施）的意見分歧，導致看護者和醫療保健專業人員感到困惑。缺乏集中的實證照護資訊來源，阻礙了就最佳實踐達成共識，尤其是在資源匱乏的地區。此外，不同文化和衛生系統對先天性疾病管理的態度差異加劇了不確定性。

COVID-19的影響

COVID-19危機為愛德華茲症候群等罕見複雜疾病患者帶來了更多挑戰。新生兒加護病房(NICU) 和小兒科的診療服務中斷，導致重症加護期間的及時干預措施被延誤。封鎖措施和醫療系統的壓力導致診斷篩檢被推遲。然而，疫情促使遠端醫療和虛擬諮商的廣泛應用，為家庭提供持續的心理社會支持和決策指導。

預測期內，支持性/安寧療護領域預計將實現最大幅度成長

由於缺乏改善病情的治療方法，預計支持性/安寧療護領域將在預測期內佔據最大的市場佔有率。這些護理方法著重於透過解決飲食障礙、呼吸系統疾病和疼痛管理來減輕患者及其家屬的身心負擔。醫院擴大整合由新生兒科醫生、護士、諮商師和社會工作者組成的多學科安寧療護團隊，以改善以病人為中心的治療效果。

預計在預測期內，鑲嵌型 18 三體症片段的複合年成長率最高。

18三體嵌合型病例預計將在預測期內實現最高成長率，這得益於其相對良好的預後和延長存活期的潛力。此類患者通常症狀較輕，更有可能從個人化治療策略中獲益。基因篩檢和核型分析技術的進步使得嵌合型的早期發現成為可能，鼓勵臨床醫生探索標靶治療的途徑。

比最大的地區

由於產前篩檢基礎設施的改善和新生兒保健設施的普及，預計亞太地區將在預測期內佔據最大的市場佔有率。在中國、印度和日本等國家，國家健康宣傳活動和早期療育計畫提高了人們對染色體異常的認知。母胎醫學的投資以及非侵入性產前檢測 (NIPT) 的進步顯著擴展了診斷範圍。

複合年成長率最高的地區

在預測期內，北美地區預計將呈現最高的複合年成長率，這得益於其強大的罕見疾病政策框架和先進的醫療基礎設施。津貼和稅額扣抵等針對罕見疾病的專門融資管道的存在，加速了該領域的研發。美國和加拿大已建立專門治療遺傳疾病的臨床護理中心網路，為複雜的新生兒病例提供多學科管理。

免費客製化服務

訂閱此報告的客戶可享有以下免費自訂選項之一：

  • 公司簡介
    • 對其他市場參與企業（最多 3 家公司）進行全面分析
    • 主要企業的SWOT分析（最多3家公司）
  • 地理細分
    • 根據客戶興趣對主要國家進行市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 透過產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 研究範圍
  • 調查方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 研究途徑
  • 研究材料
    • 主要研究資料
    • 二手研究資料
    • 先決條件

第3章市場走勢分析

  • 介紹
  • 驅動程式
  • 限制因素
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • COVID-19的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買家的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球愛德華茲氏症候群治療市場（依治療類型）

  • 介紹
  • 支持性/安寧療護
    • 心臟治療
    • 輔助餵食
    • 整形外科治療
    • 心理社會支持
    • 早期療育計劃
    • 篩檢和監測
  • 未來潛在的治療方法
    • 基因治療
    • 個人化醫療
  • 其他類型的治療

6. 全球愛德華茲氏症候群治療市場（按類型）

  • 介紹
  • 完全性18三體綜合症
  • 18三體嵌合體
  • 18部分三體症候群

7. 全球愛德華茲氏症候群治療市場（依最終用戶）

  • 介紹
  • 醫院
  • 診所
  • 門診手術中心
  • 其他

8. 全球愛德華茲氏症候群治療市場（按地區）

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第9章 主要進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第10章 公司概況

  • Thermo Fisher Scientific Inc.
  • Stryker Corporation
  • Quest Diagnostics
  • PerkinElmer Inc.
  • Natera, Inc.
  • Myriad Genetics, Inc.
  • Masimo Corporation
  • Koninklijke Philips NV
  • Invitae Corporation
  • Illumina, Inc.
  • GE HealthCare
  • F. Hoffmann-La Roche Ltd.
  • Eurofins Scientific
  • Centogene NV
  • Boston Scientific Corporation
  • Bio-Rad Laboratories, Inc.
  • Agilent Technologies, Inc.
  • Abbott Laboratories
Product Code: SMRC29994

According to Stratistics MRC, the Global Edward's Syndrome Treatment Market is accounted for $5.6 billion in 2025 and is expected to reach $8.9 billion by 2032 growing at a CAGR of 6.9% during the forecast period. Edward's Syndrome, or Trisomy 18, has no definitive cure; treatment focuses on supportive and palliative care. Medical interventions aim to manage life-threatening complications such as heart defects, feeding difficulties, and respiratory issues. Newborns may require neonatal intensive care, while long-term survivors benefit from multidisciplinary support to improve quality of life. Decisions are often guided by the severity of symptoms and family preferences. The approach emphasizes comfort, ethical considerations, and individualized care planning.

According to a 2022 review in The Journal of Pediatrics, about 50% of infants with Edward's Syndrome survive beyond the first week of life, but less than 10% live past their first year, even with intensive medical care.

Market Dynamics:

Driver:

Growing focus on palliative and comfort care

The increasing emphasis on improving the quality of life for patients with life-limiting conditions is significantly shaping the Edwards Syndrome treatment landscape. With no definitive cure currently available, the medical focus is shifting toward enhancing patient comfort through symptom management and palliative interventions. Healthcare providers are prioritizing supportive care strategies to minimize suffering and improve functional well-being, especially during neonatal and early infancy stages.

Restraint:

High mortality rate and short life expectancy

The majority of patients do not live beyond the first year of life, which impacts the scope for developing comprehensive therapeutic interventions. This short life expectancy often leads to a more conservative medical approach, with limited emphasis on aggressive treatment. Additionally, the emotional and ethical challenges surrounding decision-making for invasive procedures further limit treatment adoption.

Opportunity:

Investment in rare disease research and orphan drug designations

Strategic funding initiatives, such as orphan drug programs, are encouraging pharmaceutical companies to explore targeted therapies that cater to these underserved patient groups. Governments and regulatory authorities are offering accelerated approval pathways and financial incentives, fostering innovation in prenatal diagnostics and gene-modulating treatments. Academic institutions are also collaborating with biotech firms to explore new therapeutic angles using molecular research.

Threat:

Misinformation and lack of consistent information

Conflicting opinions on treatment protocols-particularly regarding life-sustaining interventions can lead to confusion among caregivers and healthcare professionals. Lack of centralized resources for evidence-based care impedes consensus on best practices, especially in resource-limited regions. Additionally, varying attitudes across cultures and medical systems toward managing congenital disorders exacerbate uncertainty.

Covid-19 Impact:

The COVID-19 crisis created additional difficulties for patients with rare and complex conditions like Edwards Syndrome. Disrupted access to neonatal intensive care units (NICUs) and pediatric specialists delayed timely interventions during critical care windows. Lockdowns and strained healthcare systems resulted in postponed diagnostic screenings. However, the pandemic also prompted broader adoption of telemedicine and virtual counseling, which provided families with continuity in psychosocial support and decision-making guidance.

The supportive care/palliative care segment is expected to be the largest during the forecast period

The supportive care/palliative care segment is expected to account for the largest market share during the forecast period given the absence of disease-altering therapies. These care approaches focus on easing the physical and emotional burden on patients and their families by managing feeding difficulties, respiratory issues, and pain. Hospitals are increasingly integrating interdisciplinary palliative care teams comprising neonatologists, nurses, counselors, and social workers to improve patient-centered outcomes.

The mosaic trisomy 18 segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the mosaic trisomy 18 segment is predicted to witness the highest growth rate due to comparatively better prognostic outcomes and extended survival potential. Patients with this form often exhibit milder symptoms and may benefit more from individualized treatment strategies. Advances in genetic screening and karyotyping have enhanced early detection of mosaicism, prompting clinicians to explore targeted therapeutic paths.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share owing to improved prenatal screening infrastructure, and expanding access to neonatal care facilities. Nations such as China, India, and Japan are witnessing rising awareness of chromosomal anomalies due to national health campaigns and early intervention programs. Investments in maternal-fetal medicine and advances in non-invasive prenatal testing (NIPT) have significantly enhanced diagnostic coverage.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR driven by robust rare disease policy frameworks and advanced healthcare infrastructure. The presence of dedicated funding channels for orphan diseases, including grants and tax credits, is accelerating research and development in this domain. The U.S. and Canada have established networks of clinical care centers that specialize in genetic disorders, offering multidisciplinary management for complex neonatal cases.

Key players in the market

Some of the key players in Edward's Syndrome Treatment Market include Thermo Fisher Scientific Inc., Stryker Corporation, Quest Diagnostics, PerkinElmer Inc., Natera, Inc., Myriad Genetics, Inc., Masimo Corporation, Koninklijke Philips N.V., Invitae Corporation, Illumina, Inc., GE HealthCare, F. Hoffmann-La Roche Ltd., Eurofins Scientific, Centogene N.V., Boston Scientific Corporation, Bio-Rad Laboratories, Inc., Agilent Technologies, Inc and Abbott Laboratories.

Key Developments:

In June 2025, Thermo Fisher introduced the Orbitrap Astral Zoom and Orbitrap Excedion Pro mass spectrometers at the ASMS 2025 conference, offering exceptional speed, sensitivity and resolution for biopharma and omics research.

In February 2025, Thermo Fisher entered a definitive agreement to buy Solventum's Purification & Filtration division for approximately $4.1 billion, expanding its bioprocessing and biologics manufacturing capabilities.

In January 2025, Stryker agreed to acquire Inari Medical in an all-cash deal, strengthening its peripheral vascular disease treatment portfolio and enhancing endovascular procedural offerings.

Treatment Types Covered:

  • Supportive Care/Palliative Care
  • Potential Future Therapies
  • Other Treatment Types

Types Covered:

  • Full Trisomy 18
  • Mosaic Trisomy 18
  • Partial Trisomy 18

End Users Covered:

  • Hospitals
  • Clinics
  • Ambulatory Surgical Centres
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Edward's Syndrome Treatment Market, By Treatment Type

  • 5.1 Introduction
  • 5.2 Supportive Care/Palliative Care
    • 5.2.1 Cardiac Treatment
    • 5.2.2 Assisted Feeding
    • 5.2.3 Orthopedic Treatment
    • 5.2.4 Psychosocial Support
    • 5.2.5 Early Intervention Programs
    • 5.2.6 Screening & Monitoring
  • 5.3 Potential Future Therapies
    • 5.3.1 Gene Therapy
    • 5.3.2 Personalized Medicine
  • 5.4 Other Treatment Types

6 Global Edward's Syndrome Treatment Market, By Type

  • 6.1 Introduction
  • 6.2 Full Trisomy 18
  • 6.3 Mosaic Trisomy 18
  • 6.4 Partial Trisomy 18

7 Global Edward's Syndrome Treatment Market, By End User

  • 7.1 Introduction
  • 7.2 Hospitals
  • 7.3 Clinics
  • 7.4 Ambulatory Surgical Centres
  • 7.5 Other End Users

8 Global Edward's Syndrome Treatment Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Thermo Fisher Scientific Inc.
  • 10.2 Stryker Corporation
  • 10.3 Quest Diagnostics
  • 10.4 PerkinElmer Inc.
  • 10.5 Natera, Inc.
  • 10.6 Myriad Genetics, Inc.
  • 10.7 Masimo Corporation
  • 10.8 Koninklijke Philips N.V.
  • 10.9 Invitae Corporation
  • 10.10 Illumina, Inc.
  • 10.11 GE HealthCare
  • 10.12 F. Hoffmann-La Roche Ltd.
  • 10.13 Eurofins Scientific
  • 10.14 Centogene N.V.
  • 10.15 Boston Scientific Corporation
  • 10.16 Bio-Rad Laboratories, Inc.
  • 10.17 Agilent Technologies, Inc.
  • 10.18 Abbott Laboratories

List of Tables

  • Table 1 Global Edward's Syndrome Treatment Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Edward's Syndrome Treatment Market Outlook, By Treatment Type (2024-2032) ($MN)
  • Table 3 Global Edward's Syndrome Treatment Market Outlook, By Supportive Care/Palliative Care (2024-2032) ($MN)
  • Table 4 Global Edward's Syndrome Treatment Market Outlook, By Cardiac Treatment (2024-2032) ($MN)
  • Table 5 Global Edward's Syndrome Treatment Market Outlook, By Assisted Feeding (2024-2032) ($MN)
  • Table 6 Global Edward's Syndrome Treatment Market Outlook, By Orthopedic Treatment (2024-2032) ($MN)
  • Table 7 Global Edward's Syndrome Treatment Market Outlook, By Psychosocial Support (2024-2032) ($MN)
  • Table 8 Global Edward's Syndrome Treatment Market Outlook, By Early Intervention Programs (2024-2032) ($MN)
  • Table 9 Global Edward's Syndrome Treatment Market Outlook, By Screening & Monitoring (2024-2032) ($MN)
  • Table 10 Global Edward's Syndrome Treatment Market Outlook, By Potential Future Therapies (2024-2032) ($MN)
  • Table 11 Global Edward's Syndrome Treatment Market Outlook, By Gene Therapy (2024-2032) ($MN)
  • Table 12 Global Edward's Syndrome Treatment Market Outlook, By Personalized Medicine (2024-2032) ($MN)
  • Table 13 Global Edward's Syndrome Treatment Market Outlook, By Other Treatment Types (2024-2032) ($MN)
  • Table 14 Global Edward's Syndrome Treatment Market Outlook, By Type (2024-2032) ($MN)
  • Table 15 Global Edward's Syndrome Treatment Market Outlook, By Full Trisomy 18 (2024-2032) ($MN)
  • Table 16 Global Edward's Syndrome Treatment Market Outlook, By Mosaic Trisomy 18 (2024-2032) ($MN)
  • Table 17 Global Edward's Syndrome Treatment Market Outlook, By Partial Trisomy 18 (2024-2032) ($MN)
  • Table 18 Global Edward's Syndrome Treatment Market Outlook, By End User (2024-2032) ($MN)
  • Table 19 Global Edward's Syndrome Treatment Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 20 Global Edward's Syndrome Treatment Market Outlook, By Clinics (2024-2032) ($MN)
  • Table 21 Global Edward's Syndrome Treatment Market Outlook, By Ambulatory Surgical Centres (2024-2032) ($MN)
  • Table 22 Global Edward's Syndrome Treatment Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.